Anandamide, a naturally-occurring agonist of the cannabinoid receptor, blocks adenylate cyclase at the frog neuromuscular junction

  • Van der Kloot W
  • 3


    Mendeley users who have this article in their library.
  • 21


    Citations of this article.


Anandamide (arachydonylethanolamide) is a naturally-occurring ligand of the cannabinoid receptor. When anandamide binds to its receptor, adenylate cyclase is inhibited. At the frog neuromuscular junction, anandamide lessened the increase in quantal size produced by pretreatment in hypertonic solution. It did not alter the increases in quantal size produced by insulin or by a permeable agonist of cAMP. It was known that hypertonic treatment increases quantal size by way of the cAMP-protein kinase A pathway. Anandamide had no effect on miniature endplate potential frequency (fmepp) in untreated preparations. After fmeppwas increased in the presence of a permeable cAMP agonist, anandamide brought fmeppback to resting levels. The conclusions are that the motor nerve terminal has a cannabinoid receptor. The binding of anandamide to this receptor seems to block adenylate cyclase. © 1994.

Author-supplied keywords

  • Anandamide
  • Cannabinoid
  • Cyclic AMP
  • Neuromuscular
  • Quantum
  • Synapse

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • William Van der Kloot

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free